Larimar Therapeutics (LRMR) Q1 2026 earnings summary

Executive summary

• Focused on developing nomlabofusp for Friedreich's ataxia, with multiple regulatory designations and ongoing clinical development in the U.S., EU, UK, and Canada.

• Preparing to initiate a rolling BLA for accelerated approval, with nonclinical and clinical modules to be submitted in June 2026 and CMC module in the second half of 2026.

• Breakthrough Therapy Designation granted by FDA in February 2026, supporting development for adults and children.

• Topline data from the open-label study expected in Q2 2026 to support BLA submission; first patient dosing in global Phase 3 study planned for mid-2026.

• Agreement with FDA on use of skin FXN as a surrogate endpoint for accelerated approval.

Financial highlights

• Net loss of $29.6 million for Q1 2026, compared to $29.3 million in Q1 2025.

• Operating expenses totaled $31.1 million in Q1 2026, with $25.0 million in R&D and $6.1 million in G&A.

• Cash, cash equivalents, and marketable securities were $200.4 million as of March 31, 2026, providing a projected cash runway into Q2 2027.

• Completed a $115.0 million public offering in February 2026, resulting in $107.6 million net proceeds, and a $65.0 million offering in July 2025.

• Research and development expenses decreased to $25.0 million in Q1 2026 from $26.6 million in Q1 2025, mainly due to lower manufacturing and clinical trial costs.

Outlook and guidance

• Current cash position expected to fund operations into Q2 2027.

• Plans to initiate a rolling BLA submission in June 2026 and submit final modules in the second half of 2026.

• Targeting first half 2027 for potential commercial launch, pending regulatory approval.

• Type B FDA meeting scheduled in Q2 2026 to finalize BLA data package.

• Expects continued increases in R&D and G&A expenses as clinical and commercial activities expand.